Jin Rong Jie·2025-08-18 08:45Group 1 - The Shanghai Composite Index rose by 0.85% to close at 3728.03 points, while the Hang Seng Index fell by 0.37% to close at 25176.85 points [1] - Fudan Zhangjiang's A/H premium reached 183.79%, ranking third among A/H shares [1] - Fudan Zhangjiang's A-shares closed at 10.68 yuan, with a gain of 2.01%, and H-shares closed at 4.1 Hong Kong dollars, up by 2.24% [1] Group 2 - Fudan Zhangjiang Biopharmaceutical Co., Ltd. was established in November 1996 in the Zhangjiang Hi-Tech Park, Shanghai, with notable shareholders including Shanghai Pharmaceuticals Holding Co., Ltd. [1] - The company focuses on innovative research, development, production, and sales in the biopharmaceutical sector, aiming to become a knowledge-based innovative enterprise [1] - Fudan Zhangjiang has developed competitive advantages in areas such as gene technology drugs, photodynamic therapy drugs, nanotechnology drugs, and oral solid dosage technology, with new drugs expected to be launched in the market [1]